Southern District Of New York Dismisses Putative Class Action Against Pharmaceutical Company For Failure To Allege Material Misstatement Or Omission

Publication Date21 October 2020
SubjectClass Action,Misrepresentation,Securities Exchange Act,Fiduciary Duty,Scienter,Securities Fraud,Omissions,Securities Litigation
Law FirmShearman & Sterling LLP

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT